What researchers published on Krónikus limfoid leukémia (CLL)
9522 papers, newest first.
Showing 80 of 9522
Complex karyotype and non-BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia.British journal of haematology
A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia.EJHaem
Measurable residual disease in chronic lymphocytic leukemia in real-world clinical practice: a single-center experience from 2018-2025.Frontiers in oncology
Ibrutinib dose modification and effectiveness in Japanese patients with chronic lymphocytic leukemia: a post-hoc analysis of the Orbit study.Leukemia & lymphoma
ÁttekintésChronic Lymphocytic Leukaemia as a Disease of Time: A Four-Clock Framework for Therapeutic Stewardship.European journal of haematology
CD20 antigen loss post-venetoclax/anti-CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications.British journal of haematology
Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control.EJHaem
ÁttekintésA Value-Based Framework for CLL Care: Results of a Scoping Review.Cancers
Factors Affecting Time to First Treatment in Early-Stage Chronic Lymphocytic Leukemia: A Single-Center Retrospective Cohort Study.Diagnostics (Basel, Switzerland)
Associations of Chronic Lymphocytic Leukemia (CLL) Susceptibility Variants Across the CLL Etiologic Continuum.Cancers
Can We use delayed consolidation in chronic lymphocytic leukemia?Leukemia & lymphoma
ÁttekintésArtificial Intelligence in Chronic Lymphocytic Leukemia: From Prognostic Biomarkers to Individualized Treatment Selection.Diagnostics (Basel, Switzerland)
Late-Onset Invasive Aspergillosis Following Acalabrutinib in 2 Patients With Chronic Lymphocytic Leukemia: A Case Report.Open forum infectious diseases
Optimizing Frontline Targeted Therapies in Chronic Lymphocytic Leukemia: An Italian Inter-Regional Delphi Consensus on Patient Risk Stratification, Cardiovascular Safety, and Endpoint Interpretation.European journal of haematology
EsetismertetésExtensive Native Aortic Valve Infiltration and Early Bioprosthetic Valve Degeneration in Low-Grade Chronic Lymphocytic Leukemia.JACC. Case reports
Fit for the fight: BTK inhibitors prime CAR T cells in CLL.Blood
Rapid identification of the high-risk IGLV3-21R110 subgroup of chronic lymphocytic leukemia by flow cytometry.Haematologica
Paraneoplastic spongiotic dermatitis associated with progression to treatment-requiring chronic lymphocytic leukemia.Haematologica
Intercellular transfer of FOLR2 from nurse-like cells fuels chronic lymphocytic leukemia cell activation and proliferation.Haematologica
Glucagon-like peptide-1 receptor agonist exposure is associated with lower secondary malignancy risk during watch-and-wait in chronic lymphocytic leukemia: a timevarying analysis.Haematologica
Efficacy of continuous zanubrutinib monotherapy versus fixed-duration acalabrutinib plus venetoclax or venetoclax plus obinutuzumab in treatment-naïve chronic lymphocytic leukemia: a network meta-analysis.Leukemia & lymphoma
How Many Lines of Therapy Do Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receive in Routine Clinical Practice in the United States? Real World Evidence From the Targeted Therapy Era.Clinical lymphoma, myeloma & leukemia
Social vulnerability index associates with chronic lymphocytic leukemia survival rates in the Detroit tri-county area.Cancer research communications
Borderline tuberculoid leprosy with type 1 reaction mimicking leukaemia cutis in a patient with chronic lymphocytic leukaemia on acalabrutinib.BMJ case reports
Optimizing CLL treatment after covalent BTK inhibition.Clinical advances in hematology & oncology : H&O
EsetismertetésZanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System-Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report.Cancer reports (Hoboken, N.J.)
Terminal differentiation program of CD8 T cells guides immunotherapeutic options for CLL patients.Blood
ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia.Cancer medicine
Effects of Dioscin on NLRP3 Inflammasome Expression and Apoptosis in Chronic Lymphocytic Leukemia Cells.Immunopharmacology and immunotoxicology
Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors (BTKi): A Retrospective Study From a Tertiary Healthcare Center in North India.Cureus
Real-world outcomes after second-line therapy in chronic lymphocytic leukemia: A population-based study.Leukemia research
Real-World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First-Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study.EJHaem
Decision-Making on First-Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi-Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy.Hematological oncology
The evolving evidence ecosystem in chronic lymphocytic leukemia: from linear hierarchies to integrated synthesis.Expert review of hematology
A thyroid nodule consistent with chronic lymphocytic leukemia.Endocrinology, diabetes & metabolism case reports
Aptamers in cancer research: Focus on leukemia.Chinese medical journal
Beyond age: The prognostic impact of frailty on in-hospital outcomes in chronic lymphocytic leukemia.Journal of geriatric oncology
Exanthematous drug eruption with reactive T-cell atypia in a patient with accelerated chronic lymphocytic leukemia.International journal of women's dermatology
Quantitative systems pharmacology modeling identifies synthetic lethality opportunities with DNA damage response inhibitors in ATM-deficient chronic lymphocytic leukemia - a computational simulation study.Journal of pharmacokinetics and pharmacodynamics
ÁttekintésChronic lymphocytic leukemia: recent advances and emerging therapeutic strategies.Blood research
Personalized Prediction of Venetoclax-Associated Tumor Lysis Syndrome in Acute Myeloid Leukemia Using Drug Exposure, Genetic Polymorphisms, and Clinical-Laboratory Characteristics.Drug design, development and therapy
Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real-World Study.Cancer medicine
Comment on "Costs and consequences of cardiovascular toxicity due to Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia".Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
EsetismertetésConcurrent treatment of chronic lymphocytic leukemia and acquired von Willebrand syndrome using a Bruton tyrosine kinase inhibitor: a case report.Blood transfusion = Trasfusione del sangue
EsetismertetésLeukemia Cutis at the Diagnosis of Chronic Lymphocytic Leukemia: A Case Report.Cureus
Scalable Arrayed T-cell CRISPR Screening in Autologous Tumor Co-cultures to Prioritize Combination Partners for T-cell Engagers.Current protocols
Real-World Treatment Patterns and Outcomes of Zanubrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at University of California Academic Health Centers: A Retrospective Cohort Study.Oncology and therapy
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.Leukemia
T cell-driven venetoclax resistance in chronic lymphocytic leukemia: in vivo preclinical activity of opaganib.Frontiers in immunology
EsetismertetésCD23-negative atypical chronic lymphocytic leukemia with a novel three-way translocation t(4;10;13), unmutated: immunoglobulin heavy chain variable gene, and stereotyped subset #6 (case report).The Pan African medical journal
TAILORing ibrutinib dose and plasma levels in the real-life patient with chronic lymphocytic leukemia.The Journal of pharmacology and experimental therapeutics
Correlation of Epstein-Barr virus (EBV) expressed miRNAs (BART4, BART7, and BHRF1) with chronic lymphocytic leukemia stages.Infectious agents and cancer
ÁttekintésNavigating Measurable Residual Disease as a Surrogate Endpoint in Chronic Lymphocytic Leukemia.Hematological oncology
ÁttekintésRichter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape.Biomedicines
Real-world effectiveness and safety of fixed-duration frontline venetoclax-obinutuzumab for chronic lymphocytic leukemia: A nationwide multicenter retrospective cohort study.Leukemia research
Association of Cbl-Interacting Protein CIN85 with Protein Phosphatase 2A (PP2A) Partly Confer Neoplastic Properties to Human Leukemia Cell Lines.Cells
Expression of TCTP/HRF and MCL-1 in chronic lymphocytic leukemia: implications for disease pathogenesis.Molecular biology reports
The genomic and transcriptomic landscape of chronic lymphocytic leukaemia: Insights from an integrated analysis of 275 patients.British journal of haematology
PTPN2/PTPN1 inhibition enhances ex vivo T- cell responses and potentiates mosunetuzumab activity in chronic lymphocytic leukemia.Frontiers in immunology
EsetismertetésCollision of Malignant Melanoma and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Case Report and Literature Review.Dermatopathology (Basel, Switzerland)
Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.American journal of cancer research
Pulmonary Involvement in Chronic Lymphocytic Leukemia: A Structured Diagnostic Approach to Diffuse Infiltrates-A Case Report.EJHaem
Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis.Leukemia
USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival.Molecular oncology
IκBζ target genes in chronic lymphocytic leukemia.iScience
Pirtobrutinib for the Treatment of Therapy-Resistant Chronic Lymphatic Leukemia With CNS Localization.Case reports in hematology
EsetismertetésProlonged Active SARS-CoV-2 Infection in a Patient With Chronic Lymphocytic Leukemia on Venetoclax.Cureus
TP53 mutations and IGHV in naïve chronic lymphocytic leukemia: retrospective analysis of data from a Spanish collaborative network.International journal of hematology
Immunoglobulin kinetics and infection patterns across venetoclax-based regimens in chronic lymphocytic leukemia.Leukemia & lymphoma
Survival Outcomes in Chronic Lymphocytic Leukemia During the Novel Agent Era: A Population-Based Analysis.Cancer medicine
A Novel BCL2 Translocation and Concurrent Chromosome 13q14 Deletion in Chronic Lymphocytic Leukemia: A Case Report.EJHaem
MRD-guided ibrutinib plus venetoclax improves quality of life in relapsed/refractory CLL: HOVON 141/VISION trial results.Blood advances
EsetismertetésAn Atypical Presentation of Richter's Transformation in Chronic Lymphocytic Leukemia: Stroke-Like Onset With Multiorgan Involvement Including the Heart and Seminal Vesicles.Cureus
Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.Leukemia
Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation.Blood advances
Megfigyeléses vizsgálatEfficacy of continuous ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia with high-burden and low-burden TP53 mutations: Multicenter retrospective analysis of the Polish Adult Leukemia Group (PALG).Advances in clinical and experimental medicine : official organ Wroclaw Medical University
ÁttekintésStereotyped CLL-like immunoglobulin rearrangements in healthy repertoires: implications for leukemogenesis.Frontiers in immunology
Treatment adherence in chronic lymphocytic leukaemia and chronic myeloid leukaemia: An integrative review.Enfermeria clinica
Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expression.Haematologica
The maturation of precision medicine into pragmatic, patient-centered care: A commentary on the 2026 EHA CLL Guidelines.HemaSphere